Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies - PubMed (original) (raw)
. 2013 Jan 1;31(1):128-30.
doi: 10.1200/JCO.2012.44.4281. Epub 2012 Oct 8.
Affiliations
- PMID: 23045586
- DOI: 10.1200/JCO.2012.44.4281
Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies
Adrian Wiestner. J Clin Oncol. 2013.
No abstract available
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources